New Trial Medication for Pulmonary Arterial Hypertension Request More Information Trial Objective The new investigational drug Ralinepag is designed to help the body receive prostacyclin known to widened blood vessels and relax artery walls, and potentially improve blood flow in adults with Pulmonary Arterial Hypertension (PAH). The ADVANCE OUTCOMES study is evaluating the effects of adding Ralinepag, to patients’ current PAH therapies. Once screened, participants will have 16 weeks to find their optimal dose before continuing to treatment. Participants will have the option to continue in an extension study of Ralinepag (ADVANCE-extension) if they are eligible. The extension study will look at the effect of Ralinepag over a longer period of time. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Adults between 18 and 75 who have been diagnosed with Pulmonary Arterial Hypertension. Age: 18-75 Gender: Any Gender Estimated Time Commitment Up to 42 months The first four weeks will be spent screening participants. This will be followed by 16 weeks to find the optimal dosage for participants, after which treatment will start and patients will check in every 12 weeks until the end of the study, which is individual to each participant. After treatment there will be a final follow up after 30 days. There will be both clinic visits and telephone calls throughout the trial. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Jennifer Underwood 303.398.1518 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors United Therapeutics Principal Investigators Marjorie Patricia George, MD + × Marjorie Patricia George, MD Associate Professor Director, Pulmonary Hypertension Program Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Co-Investigators Andrew Freeman, MD, FACC, FACP + × Andrew Freeman, MD, FACC, FACP Associate Professor Director of Cardiovascular Prevention and Wellness Director, Clinical Cardiology & Operations Director, Anticoagulation Clinic Division of Cardiology Department of Medicine View Full Profile Patient Rating 4.7 out of 5 stars Make an Appoinment Darlene Kim, MD, FACC + × Darlene Kim, MD, FACC Associate Professor Department of Medicine Division of Cardiology View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective The new investigational drug Ralinepag is designed to help the body receive prostacyclin known to widened blood vessels and relax artery walls, and potentially improve blood flow in adults with Pulmonary Arterial Hypertension (PAH). The ADVANCE OUTCOMES study is evaluating the effects of adding Ralinepag, to patients’ current PAH therapies. Once screened, participants will have 16 weeks to find their optimal dose before continuing to treatment. Participants will have the option to continue in an extension study of Ralinepag (ADVANCE-extension) if they are eligible. The extension study will look at the effect of Ralinepag over a longer period of time.